Cell of origin for malignant gliomas and its implication in therapeutic development
Related Experiment Video
Updated: Apr 18, 2026
Method for Novel Anti-Cancer Drug Development using Tumor Explants of Surgical Specimens
Published on: July 29, 2011
Hui Zong1, Luis F Parada2, Suzanne J Baker3
1Department of Microbiology, Immunology, and Cancer Biology, University of Virginia, Charlottesville, Virginia 22908.
Abstract:
Malignant glioma remains incurable despite tremendous advancement in basic research and clinical practice. The identification of the cell(s) of origin should provide deep insights into leverage points for one to halt disease progression. Here we summarize recent studies that support the notion that neural stem cell (NSC), astrocyte, and oligodendrocyte precursor cell (OPC) can all serve as the cell of origin. We also lay out important considerations on technical rigor for further exploring this subject. Finally, we share perspectives on how one could apply the knowledge of cell of origin to develop effective treatment methods. Although it will be a difficult battle, victory should be within reach as along as we continue to assimilate new information and facilitate the collaboration among basic scientists, translational researchers, and clinicians.
Insights
Malignant glioma may originate from neural stem cells, astrocytes, or oligodendrocyte precursor cells. Understanding the cell of origin is key to developing new treatments for this incurable brain cancer.
Area of Science:
- Neuro-oncology
- Cancer Stem Cell Biology
Background:
- Malignant glioma is an aggressive brain tumor with poor prognosis.
- Current treatments have limited efficacy, highlighting the need for novel therapeutic strategies.
- Identifying the cell of origin is crucial for understanding glioma development and progression.
Purpose of the Study:
- To review recent evidence on the cell(s) of origin for malignant glioma.
- To discuss technical considerations for future research in this area.
- To propose strategies for developing effective treatments based on cell of origin knowledge.
Main Methods:
- Literature review of studies investigating glioma cell of origin.
- Synthesis of findings regarding neural stem cells (NSCs), astrocytes, and oligodendrocyte precursor cells (OPCs) as potential origins.
- Discussion of technical rigor and future research directions.
Main Results:
- Evidence suggests that NSCs, astrocytes, and OPCs can all serve as the cell of origin for malignant glioma.
- Key technical considerations for rigorous investigation of glioma cell of origin are outlined.
- Potential therapeutic avenues based on cell of origin are explored.
Conclusions:
- Malignant glioma can arise from multiple cell types within the brain.
- Further research into the cell of origin is essential for advancing treatment strategies.
- Collaborative efforts between basic scientists, translational researchers, and clinicians are vital for overcoming glioma.
